Showing 2311-2320 of 2494 results for "".
- COVID-19 Vaccine Safety Efforts to Feature App Tracking of Vulnerable Groupshttps://modernod.com/news/covid-19-vaccine-safety-efforts-to-feature-app-tracking-of-vulnerable-groups/2478501/Government health officials and drugmakers plan to roll out extra tools to detect whether COVID-19 vaccines cause any serious side effects once the shots are cleared for widespread use, aiming to fill gaps in existing safeguards given the expected speed and scope of
- GenSight Biologics Reports Validation of Lumevoq Marketing Authorization Application (MAA) by European Medicines Agencyhttps://modernod.com/news/gensight-biologics-reports-validation-of-lumevoq-marketing-authorization-application-maa-by-european-medicines-agency/2478488/GenSight Biologics reported that the Lumevoq Marketing Authorization Application (MAA) passed the validation checks required for submissions to the European Medicines Agency (EMA), triggering the official start of the MAA review procedure. The application for use of Lumevoq gene therapy to treat
- Retina Consultants of America Announces New Alliancehttps://modernod.com/news/retina-consultants-of-america-announces-new-alliance-2/2478486/Retina Consultants of America (RCA) has added South Carolina-based Palmetto Retina Center (PRC) to its consortium of practices. This is the seventh retina specialty practice to join RCA. Palmetto Retina Center is comprised of five retina specialists across six offices serving South Carolin
- Internal Documents Reveal COVID-19 Hospitalization Data The Government Keeps Hiddenhttps://modernod.com/news/internal-documents-reveal-covid-19-hospitalization-data-the-government-keeps-hidden/2478485/As coronavirus cases rise swiftly around the country, surpassing both the spring and summer surges, health officials brace for a coming wave of hospitalizations and deaths. Knowing which hospitals in which communities are reaching capacity could be key to an effective response to the growing cris
- Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039https://modernod.com/news/nicox-granted-new-patent-for-ncx-470-extending-exclusivity-in-europe-to-2039/2478471/Nicox announced that the European Patent Office has granted a formulation patent for NCX 470, extending the European exclusivity to 2039. The equivalent U.S. patent has already been granted, and NCX 470 is also covered by granted composition of matter patents. “We are pleased that our form
- Study of Lilly’s COVID-19 Antibody LY-CoV555 Paused Over Potential Safety Issuehttps://modernod.com/news/study-of-lillys-covid-19-antibody-ly-cov555-paused-over-potential-safety-issue/2478416/A phase 3 trial of Eli Lilly’s investigational monoclonal antibody LY-CoV555 for the treatment of COVID-19 has been temporarily suspended out of an “abundance of caution” because of a “potential safety concern,” according to emails that government officials sent on T
- Equinox Ophthalmic Appoints Stuart Raetzman as Executive Chairhttps://modernod.com/news/equinox-ophthalmic-appoints-stuart-raetzman-as-executive-chair/2478384/Equinox Ophthalmic announced the appointment of Stuart Raetzman as Executive Chairman. Company founder, John Berdahl, MD, will continue to serve on the Board of Directors and as Chief Medical Officer. Equinox Ophthalmic is a company focused on addressing the unmet need in glau
- John Weiss Launches the Merilas 810 Shortpulse Laser in the UKhttps://modernod.com/news/john-weiss-launches-the-merilas-810-shortpulse-laser-in-the-uk/2478380/John Weiss & Son has announced the launch of the Merilas 810 shortpulse laser in the UK. The Merilas 810 shortpulse laser provides glaucoma and retina treatments and offers new laser therapy for advanced and end-stage glaucoma. The system offers Transscleral Cyclophotocoagulation (TSCP
- Beovu Now Available in Canada, Receives Positive Reimbursement Recommendationhttps://modernod.com/news/beovu-now-available-in-canada-receives-positive-reimbursement-recommendation/2478363/Novartis Pharmaceuticals Canada has announced that Beovu (brolucizumab injection) is now available in Canada for the treatment of wet age-related macular degeneration (AMD). The anti-VEGF therapy for wet AMD offers the option for eligible patients to start on 3-mo
- New Company TearRestore Launches Reusable Heat Packs to Target the Meibomian Glandshttps://modernod.com/news/new-company-tearrestore-launches-reusable-heat-packs-to-target-the-meibomian-glands/2478355/New company TearRestore is seeking to simplify warm compress treatment by offering the proprietary TearRestore product. The product utilizes specially designed reusable heat packs to target the Meibomian glands while